Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Kaposi's sarcoma-associated herpesvirus ORF54/dUTPase downregulates a ligand for the NK activating receptor NKp44.

Madrid AS, Ganem D.

J Virol. 2012 Aug;86(16):8693-704. doi: 10.1128/JVI.00252-12. Epub 2012 Jun 6.

2.

Killing of Kaposi's sarcoma-associated herpesvirus-infected fibroblasts during latent infection by activated natural killer cells.

Matthews NC, Goodier MR, Robey RC, Bower M, Gotch FM.

Eur J Immunol. 2011 Jul;41(7):1958-68. doi: 10.1002/eji.201040661. Epub 2011 May 27.

3.

The anti-interferon activity of conserved viral dUTPase ORF54 is essential for an effective MHV-68 infection.

Leang RS, Wu TT, Hwang S, Liang LT, Tong L, Truong JT, Sun R.

PLoS Pathog. 2011 Oct;7(10):e1002292. doi: 10.1371/journal.ppat.1002292. Epub 2011 Oct 6.

4.

Natural killer cell evasion by an E3 ubiquitin ligase from Kaposi's sarcoma-associated herpesvirus.

Thomas M, Wills M, Lehner PJ.

Biochem Soc Trans. 2008 Jun;36(Pt 3):459-63. doi: 10.1042/BST0360459. Review.

PMID:
18481981
5.

Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) ORF54 encodes a functional dUTPase expressed in the lytic replication cycle.

Kremmer E, Sommer P, Holzer D, Galetsky SA, Molochkov VA, Gurtsevitch V, Winkelmann C, Lisner R, Niedobitek G, Grässer FA.

J Gen Virol. 1999 May;80 ( Pt 5):1305-10.

PMID:
10355777
7.

Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein.

Ishido S, Choi JK, Lee BS, Wang C, DeMaria M, Johnson RP, Cohen GB, Jung JU.

Immunity. 2000 Sep;13(3):365-74.

8.

Immune evasion strategies of Kaposi's sarcoma-associated herpesvirus.

Means RE, Choi JK, Nakamura H, Chung YH, Ishido S, Jung JU.

Curr Top Microbiol Immunol. 2002;269:187-201. Review.

PMID:
12224509
9.

Identification of a cellular ligand for the natural cytotoxicity receptor NKp44.

Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debré P, Vieillard V.

Blood. 2013 Oct 24;122(17):2935-42. doi: 10.1182/blood-2013-03-489054. Epub 2013 Aug 19.

13.

Immune evasion in Kaposi's sarcoma-associated herpes virus associated oncogenesis.

Liang C, Lee JS, Jung JU.

Semin Cancer Biol. 2008 Dec;18(6):423-36. doi: 10.1016/j.semcancer.2008.09.003. Epub 2008 Oct 2. Review.

PMID:
18948197
14.

Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi's sarcoma-associated herpesvirus.

Chiou CJ, Poole LJ, Kim PS, Ciufo DM, Cannon JS, ap Rhys CM, Alcendor DJ, Zong JC, Ambinder RF, Hayward GS.

J Virol. 2002 Apr;76(7):3421-39.

16.

Persistent activation of STAT3 by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells.

Punjabi AS, Carroll PA, Chen L, Lagunoff M.

J Virol. 2007 Mar;81(5):2449-58. Epub 2006 Dec 6.

18.

Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression.

Sharma-Walia N, Raghu H, Sadagopan S, Sivakumar R, Veettil MV, Naranatt PP, Smith MM, Chandran B.

J Virol. 2006 Jul;80(13):6534-52.

20.

Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells.

Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O.

Cell Host Microbe. 2009 Apr 23;5(4):376-85. doi: 10.1016/j.chom.2009.03.003.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk